Business Wire

NJ-IEEE

15.9.2021 16:37:03 CEST | Business Wire | Press release

Share
IEEE Launches New Standard to Address Ethical Concerns During Systems Design

IEEE, the world's largest technical professional organization dedicated to advancing technology for humanity, and the IEEE Standards Association (IEEE SA) today announced the launch of IEEE 7000™-2021 - IEEE Standard Model Process for Addressing Ethical Concerns During System Design that provides a clear methodology to analyze human and social values relevant for an ethical system engineering effort.

IEEE 7000-2021 is recommended for use by organizations that seek to apply broader ethical value criteria and minimize risk, thereby helping to strengthen relationships with their end users and customers. Organizations may apply this first of its kind standard across multiple levels including concept exploration, system requirements definition, or development of new or revised products or services.

“Engineers, their managers, and other stakeholders benefit from well-defined processes for considering ethical issues along with the usual concerns of system performance and functionality early in the system life cycle,” said Konstantinos Karachalios, Managing Director of IEEE SA. “End users can be unaware of the ethical considerations regarding the products and services they use; this is why IEEE supported the launch of the IEEE 7000 series of standards including this standard that also complements our Ethics Certification Program for Autonomous and Intelligent Systems (ECPAIS) certification criteria offering. It is only by rigorously prioritizing ethical concerns at the outset of design that manufacturers, engineers, and technologists can responsibly align products and services with results honoring the contextual values of customers, citizens, and society at large.”

This standard provides:

  • a system engineering standard approach integrating human and social values into traditional systems engineering and design.
  • processes for engineers to translate stakeholder values and ethical considerations into system requirements and design practices.
  • a systematic, transparent, and traceable approach to address ethically-oriented regulatory obligations in the design of autonomous intelligent systems.

“Value-based Engineering (VbE), a methodology providing ways to elicit, conceptualize, prioritize and respect end user values in system design, is at the heart of IEEE 7000-2021 and provides companies with a highly practical approach to master the values based challenges of their digital transformation,” said Dr. Sarah Spiekermann, Chair of The Institute for Information Systems & Society at Vienna University of Economics and Business (WU Vienna) and Vice-Chair of IEEE 7000-2021. "IEEE 7000-2021 test users identified ten issues per person involved in the project, demonstrating that the utilization of value-based Engineering can lead to fewer project risks and exponential innovation. This is a massive improvement relative to current technical roadmap processes."

A key part of digital transformation provided by IEEE 7000-2021 comes in addressing risk. Where traditional evaluations of technological risk may focus largely on areas of physical harm, the VbE methodology provides a broader lens to consider also potential value harms associated with product or systems design. This makes the standard unique and deeply important in terms of ease of adoption of applied ethics methodologies in emerging technologies such as AI.

The use of this standard could help organizations better earn and keep the trust of end-users and stakeholders by directly addressing ethical concerns upfront, leading to greater market acceptance of their products, services, or systems.

For more information, to purchase, or to view a read-only version of the IEEE 7000-2021 Standard, click here .

To learn more about IEEE SA or about any of its many market-driven initiatives, visit us on Facebook , follow us on Twitter , connect with us on LinkedIn , or on the Beyond Standards Blog .

About the IEEE Standards Association

IEEE Standards Association (IEEE SA) is a collaborative organization where innovators raise the world's standards for technology. IEEE SA provides a globally open, consensus-building environment and platform that empowers people to work together in the development of leading-edge, market-relevant technology standards, and industry solutions shaping a better, safer, and sustainable world. For more information, visit https://standards.ieee.org .

About IEEE

IEEE is the world’s largest technical professional organization dedicated to advancing technology for the benefit of humanity. Through its highly cited publications, conferences, technology standards, and professional and educational activities, IEEE is the trusted voice in a wide variety of areas ranging from aerospace systems, computers, and telecommunications to biomedical engineering, electric power, and consumer electronics. Learn more at https://www.ieee.org .

Link:

ClickThru

Social Media:

https://www.facebook.com/ieeesa/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye